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Abstract
The second case of magA+ rmpA+ hypermucoviscosity phenotype Klebsiella pneumoniae infection was documented in Canada, in an immi-
grant from Algeria. To ascertain whether this represented recent importation of the strain or local transmission within Canada, a retro-
spective study of K. pneumoniae bacteraemia was conducted in the region, from 1997 to 2007, and 411 episodes were identiﬁed. No
epidemiological evidence for local transmission of this strain was found. However, for the ﬁrst time, the population incidence of K. pneu-
moniae bacteraemia was determined, which increased by 82% between 1997 and 2007, from 10.2 to 18.7 per 100 000 inhabitants. Inci-
dence increased dramatically with age and with the presence of diabetes, but remained stable over time within each stratum. The
proportion of patients with K. pneumoniae bacteraemia who were diabetic increased from 26% (1997–2004) to 42% (2005–2007). The
rising incidence of K. pneumoniae bacteraemia may represent an unexpected consequence of the expanding population of adult diabetics.
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Introduction
Klebsiella pneumoniae, a Gram-negative rod that forms large
mucoid colonies owing to its polysaccharide capsule, causes
a wide spectrum of community-acquired and nosocomial
infections. Over the past two decades, a novel hypermuco-
viscosity (HV) phenotype of K. pneumoniae, characterized by
the formation of elongated (>5 mm) mucoviscous strings
when a loop is passed through the colony, has been
described in Taiwan where, concomitantly, a distinctively
invasive syndrome of bacteraemia with liver abscess
emerged, sometimes complicated by meningitis, endoph-
thalmitis or other metastatic suppurative foci [1–4]. This
phenotype is associated with the magA (mucoviscosity associ-
ated gene A) and rmpA (regulator of mucoid phenotype)
genes and the K1 serotype [3,5–7]. To our knowledge, this
strain has not yet been reported in Europe. The ﬁrst case in
North America was diagnosed in a Filipino migrant who pre-
sented with a liver abscess [5]. Two more cases of Asian
patients with a liver abscess were described in Texas and
Manitoba [8,9]. We report the second case of infection with
the magA+ rmpA+ strain of HV K. pneumoniae in Canada, in a
patient who had recently migrated from Algeria, a country
not known to have endemic HV K. pneumoniae. To ascertain
whether this represented recent importation of the strain by
the patient or local transmission within Canada, we con-
ducted a retrospective study of K. pneumoniae bacteraemia in
our region, looking for changes in the incidence, clinical char-
acteristics and mortality attributed to this infection. This
allowed us to document for the ﬁrst time the epidemiology
of K. pneumoniae bacteraemia at a population level. As diabe-
tes mellitus is an important predisposing factor for infection
with K. pneumoniae, including the HV phenotype and other
strains [1,3], we paid particular attention to the role of this
chronic disease in modulating the incidence of K. pneumoniae
bacteraemia.
Case Report
The patient was a 47-year-old male asylum seeker, who
allegedly travelled from Algeria to Canada 6 weeks prior to
admission. He had been previously healthy except for type 2
diabetes mellitus, treated with oral hypoglycaemic agents. He
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02912.x
presented with a 3-week history of fever, dysuria and left
thigh pain. He appeared toxic and jaundiced. His temperature
was 39.5C. Palpation of the inner thigh was painful with no
apparent inﬂammatory signs. His prostate was enlarged and
tender. His leucocyte count was 27.1 · 109/L, glycaemia
22.5 mmol/L, glycosylated haemoglobin 10.8%, and liver func-
tion tests showed cholestatic perturbations. Urine analysis
showed leukocyturia and ciproﬂoxacin was started. A com-
puted tomography (CT) scan of the abdomen and pelvis
demonstrated two liver collections, the largest measuring
6.5 · 5.5 cm. The prostate was enlarged with multiple col-
lections suggestive of abscesses. A CT scan of the left thigh
showed a large abscess for which the patient underwent sur-
gical drainage. Specimens from the thigh abscess, the percu-
taneous hepatic drainage, as well as from blood and urine,
grew K. pneumoniae sensitive to ceftazidime, ceftriaxone, cip-
roﬂoxacin, gentamicin and carbapenems. The patient underwent
a trans-urethral resection of the prostate. Ophthalmological
evaluation did not reveal endophthalmitis. Hepatic drainage
continued for 5 weeks. He was discharged with outpatient
ertapenem. His clinical course was favourable. On blood
agar, the K. pneumoniae isolate grew as hypermucoviscous
colonies and displayed a positive string test. The organism
was sent to the University of Washington where the magA
and rmpA genes were detected by PCR [5].
Methods
Data collection
We reviewed all cases of K. pneumoniae bacteraemia diag-
nosed between January 1997 and December 2007 at the Cen-
tre Hospitalier Universitaire de Sherbrooke (CHUS), a 686-
bed tertiary-care hospital in the province of Quebec, Canada.
CHUS has the only microbiology laboratory in the city of
Sherbrooke (population in 2007: 149 807); for this subpopula-
tion, hospital data can be translated into population incidence.
CHUS also provides secondary and tertiary care to a larger
population. We searched the microbiology laboratory records
and the hospital’s computerized medical records to identify all
patients in whom a K. pneumoniae bacteraemia had been docu-
mented. A patient could be included more than once if bacte-
raemic episodes occurred ‡30 days apart. Episodes of
K. pneumoniae bacteraemia separated by less than a month
were considered as relapses or persistence of the initial epi-
sode. Authorization for retrospective review of patients’
records was granted by the hospital’s director of professional
services. Records were reviewed to collect: demographic
information; presence of diabetes; immunosuppressive or sys-
temic corticosteroid therapy; recent antibiotic use; recent
surgical or invasive procedures; hospitalizations within
the past year; underlying biliary or urinary tract anomalies;
anatomical sources of infection; antimicrobial susceptibility
test results and treatment.
Deﬁnitions and outcomes
Recent antibiotic exposure was deﬁned as any antibiotic used
for ‡48 h in the month preceding the bacteraemia. Invasive
procedures included upper or lower endoscopy, endoscopic
retrograde cholangio-pancreatography, nephrostomy or cys-
toscopy performed within 72 h before the bacteraemia. Nos-
ocomial bacteraemia was deﬁned as occurring >48 h after
hospital admission or <14 days after discharge. Healthcare-
associated bacteraemia included episodes in patients hospital-
ized in the previous year, residing in long-term care facilities,
receiving chronic dialysis or cancer chemotherapy, or having
an intravascular catheter or indwelling urinary catheter at
home. All other episodes were considered community
acquired. Biliary tract anomalies included lithiasis, stents or
cholangiocarcinoma. Urinary tract anomalies included lithia-
sis, double-J ureteral stents, permanent indwelling catheter
or ileal bladder. We considered intensive care unit (ICU)
admission, use of vasopressors for septic shock and mechani-
cal ventilation to be related to K. pneumoniae bacteraemia if
initiated within 48 h of its onset.
The primary outcome was infection-related 30-day mortal-
ity. Secondary outcomes included ICU admission, septic
shock, mechanical ventilation, all-cause mortality or relapses
within 30 days of onset of bacteraemia. To determine
whether mortality had been caused by K. pneumoniae bacter-
aemia or concomitant illnesses, we relied on physicians’
notes in the days prior to death, discharge diagnoses, pres-
ence of other rapidly fatal conditions and whether aggressive
supportive care had been provided.
Non-bacteraemic K. pneumoniae infection at selected sites
To identify non-bacteraemic infections potentially caused by
HV K. pneumoniae at other sites, we identiﬁed through dis-
charge diagnoses all cases of liver abscesses, bacterial menin-
gitis and endophthalmitis during the same 1997–2007 period.
Cultures of appropriate specimens were reviewed to deter-
mine the bacterial aetiology.
Population incidence
The measures of population incidence were restricted to
cases occurring among inhabitants of Sherbrooke, for whom
our institution is the only microbiology laboratory, capturing
all cases of K. pneumoniae pneumonia within this subpopula-
tion. To calculate the age-speciﬁc incidence among residents
of Sherbrooke, census data from the Quebec Statistical Insti-
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tute were used for denominators [10]. To stratify between
diabetics and non-diabetics, the number of prevalent cases of
diabetes within the same Sherbrooke population was esti-
mated from the Med-Echo provincial hospital discharges
database (any hospital admission with a diagnosis of diabetes,
or one of 16 complications of diabetes) and from the data-
base of the Re´gie d’Assurance-Maladie du Que´bec (at least
two physician billings with a diagnosis of diabetes within the
last 2 years). This algorithm has been validated and is widely
used in Canada by the National Diabetes Surveillance System
(NDSS) [11,12]. Residence in Sherbrooke was deﬁned
according to patients’ postal codes. These measures of the
prevalence of diabetes were available only for adults and for
the period 1997–2004. Because in Quebec all medical care is
paid for by the provincial government, and in Sherbrooke a
single hospital provides inpatient care, we would also capture
almost all patients diagnosed with diabetes.
Statistical analysis
Data were analysed with STATA 8.0 (StataCorp LP, College
Station, TX, USA). Proportions were compared with the chi-
square test or Fisher’s exact test. Logistic regression was
used for multivariate analysis of risk factors for mortality,
and results are presented as adjusted odds ratios (AOR)
with 95% conﬁdence intervals (CI). Models were built up
sequentially, starting with the variable most strongly associ-
ated with the outcome and continuing until no other variable
reached signiﬁcance. Then, each variable was dropped in turn
to assess its effect. Different models were compared with
the likelihood ratio test. We kept in the ﬁnal model variables
that signiﬁcantly enhanced the ﬁt at the p £0.05 level. Inter-
actions were sought between these variables.
Results
Table 1 shows the demographic and clinical characteristics of
patients according to year of diagnosis. There was little
change over time in the age and gender distribution, risk fac-
tors for K. pneumoniae bacteraemia or anatomical sources.
Pyelonephritis and biliary tract sepsis were the most com-
mon sources. One-third of the patients were diabetic, but
the prevalence of diabetes increased signiﬁcantly in 2005–
2007. Resistance to third-generation cephalosporins or cip-
roﬂoxacin remained very uncommon. There was no change
in the severity of infection as measured by ICU admission,
septic shock, need for ventilatory support, all-cause mortality
and infection-related mortality. Demographic and clinical
characteristics were similar in diabetic and non-diabetic
patients (data not shown). During the period of observation,
no cases of K. pneumoniae meningitis or endophthalm-
itis occurred. There were ﬁve cases with bacteraemic
K. pneumoniae hepatic abscess, and only two cases of non-
bacteraemic liver abscess (one in 2002, the other in 2005).
Of these seven cases, three occurred in the setting of cho-
langitis or cholecystis and one after Whipple’s procedure for
pancreatic cancer.
Table 2 shows the risk factors for infection-related mor-
tality within 30 days of onset of bacteraemia. In multivariate
analysis, the independent risk factors for infection-related
mortality were hospital acquisition, polymicrobial bactera-
emia, pneumonia as the source and lack of effective treat-
ment within the ﬁrst 24 h. When ﬁtted into this model,
diabetes mellitus was not associated with mortality (AOR:
1.17, 95% CI: 0.56–2.46, p 0.67).
Annual incidence of K. pneumoniae bacteraemia in Sher-
brooke increased progressively during the study period, from
10.2 to 18.7 per 100 000 (Table 3). The increase in incidence
was noted for community-acquired, healthcare-associated or
TABLE 1. Characteristics of patients with Klebsiella pneumo-
niae bacteraemia, 1997–2007
1997–2000
(n = 111)
2001–2004
(n = 169)
2005–2007
(n = 131)
Age, years (%)
<18 2 (2) 4 (2) 9 (7)
18–64 29 (26) 46 (27) 43 (33)
‡65 80 (72) 119 (70) 79 (60)
Gender (%)
Male 57 (51) 84 (50) 65 (50)
Female 54 (49) 85 (50) 66 (50)
Site of acquisition (%)
Community 35 (32) 50 (30) 38 (29)
Healthcare associated 30 (27) 57 (34) 48 (37)
Hospital 46 (41) 62 (37) 45 (34)
Invasive procedure, last 72 h (%) 5 (5) 12 (7) 13 (10)
Underlying biliary tract anomaly (%) 40 (36) 66 (39) 50 (38)
Underlying urinary tract anomaly (%) 25 (23) 44 (26) 28 (22)
Diabetes mellitus (%) 31 (28) 42 (25) 55 (42)
Other pathogen in blood culture (%) 24 (22) 51 (30) 34 (26)
Antimicrobial resistance (%)
Resistant to third generation
cephalosporins
0 (0) 2 (1) 1 (1)
Resistant to ciproﬂoxacin 2 (2) 2 (1) 2 (2)
Sources (%)
Pyelonephritis 31 (28) 60 (35) 43 (33)
Cholangitis/cholecystitis 33 (30) 42 (25) 38 (29)
Pneumonia/empyema 9 (8) 6 (4) 11 (8)
Liver abscess 1 (1) 1 (1) 3 (2)
Abscess at other sites 3 (3) 4 (2) 8 (6)
Other intra-abdominal infections 17 (15) 14 (8) 10 (8)
Soft tissue infections 1 (1) 5 (3) 2 (2)
Catheter sepsis/endovascular 7 (6) 12 (7) 15 (11)
Primary bacteremia
(no source identiﬁed)
17 (15) 34 (20) 11 (8)
Outcomes (%)
ICU admission 33 (30) 43 (25) 40 (31)
Septic shock 13 (12) 21 (12) 25 (19)
Need for mechanical ventilation 11 (10) 11 (6) 18 (14)
30-day mortality, all causes 17 (15) 24 (14) 22 (17)
30-day mortality attributed to
K. pneumoniae infection
13 (12) 17 (10) 13 (10)
Recurrence of bacteremia
within 30 days
2 (2) 5 (3) 5 (4)
p-Values >0.05 for all comparisons, excepted diabetes for which p 0.004.
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hospital-acquired infections. Incidence was much higher
among elderly individuals: for the whole period, incidence
was 5.4 per 100 000 among adults aged 18–64 years, and
82.6 per 100 000 among those aged ‡65 years. Among the
former, incidence was up to 21 times higher in diabetics than
non-diabetics. Among the elderly, incidence in diabetics was
2–3 times higher than in non-diabetics, and was higher than
300 per 100 000 throughout the period of observation.
Discussion
We found no epidemiological evidence of local transmission
of the magA+ rmpA+ HV K. pneumoniae strain prior to the
arrival of our patient in Canada, nor after his hospitalization.
During the study period, there was no increase in the fre-
quency of K. pneumoniae liver abscess and not a single case
of K. pneumoniae meningitis or endophthalmitis. We can not
rule out, however, the possibility that some inpatients
became colonized with the HV strain, without developing
clinical consequences. The exact whereabouts of the index
patient before his arrival into Canada are uncertain: although
he asserted that he had come directly from Algeria, a coun-
try not known to be endemic for HV K. pneumoniae, and had
not visited Asia recently. He was, however, seeking asylum
and would have had good reasons to conceal that he had
passed through a third country. Recent publications from
Algeria and Tunisia on K. pneumoniae infections focused on
CTX-M b-lactamase-producing strains but did not report the
HV phenotype; [13,14] however, the rmpA+ HV phenotype
was already present in South Africa by 1996–1997 [15].
This is the ﬁrst study measuring the population incidence
of K. pneumoniae bacteraemia. We documented an 82%
increase in incidence during the study period, and a dramatic
age-related gradient. The aging of the population contributed
to this rising incidence; the proportion of individuals aged
‡65 years increased from 13.1% to 15.3% during that inter-
val, a relative increase of 17% [10]. Simultaneously, there
TABLE 2. Risk factors for infection-related mortality within
30 days of onset of Klebsiella pneumoniae bacteraemia,
1997–2007
Infection
related
mortality/
total (%)
Crude odds
ratio
(95% CI)
Adjusted
odds ratio
(95% CI)
Age, years
<18 2/15 (13.3) 1.66 (0.33–8.43) NS
18–64 10/118 (8.5) 1.00
‡65 31/278 (11.2) 1.35 (0.64–2.85)
Gender
Female 21/205 (10.2) 1.00 NS
Male 22/206 (10.7) 1.04 (0.55–1.96)
Site of acquisition
Community 7/123 (5.7) 1.00 1.00
Healthcare-associated 12/135 (8.9) 1.63 (0.62–4.28) 1.42 (0.52–3.89)
Hospital 24/153 (15.7) 3.11 (1.29–7.48)a 2.99 (1.15–7.76)a
Systemic corticosteroids or immunosuppressive drugs
No 33/357 (9.2) 1.00 NS
Yes 10/54 (18.5) 2.24 (1.03–4.86)a
Underlying biliary tract anomaly
No 33/255 (12.9) 1.00 NS
Yes 10/156 (6.4) 0.46 (0.22–0.96)a
Underlying urinary tract anomaly
No 38/313 (12.1) 1.00 NS
Yes 5/97 (5.2) 0.39 (0.15–1.03)
Diabetes mellitus
No 29/283 (10.2) 1.00 NS
Yes 14/128 (10.9) 1.08 (0.55–2.12)
Other pathogen in blood culture
No 24/302 (7.9) 1.00 1.00
Yes 19/109 (17.4) 2.42 (1.27–4.62) 2.44 (1.20–4.96)a
Sources
Pyelonephritisc 7/132 (5.3) 1.00 1.00
Cholangitis/cholecystitis 9/113 (8.0) 1.53 (0.55–4.25) 1.66 (0.57–4.85)
Pneumonia 11/26 (42.3) 13.10 (4.41–38.89)b 12.35 (3.99–38.27)b
All other sources 6/76 (7.9) 1.53 (0.49–4.73) 0.90 (0.28–2.95)
No source identiﬁed 10/62 (16.1) 3.43 (1.24–9.51)a 2.13 (0.73–6.24)
Treatment within the ﬁrst 24 h
Effective antibiotics 34/367(9.3) 1.00 1.00
No effective antibiotic 9/42(21.4) 2.68 (1.18–6.07)a 2.59 (1.03–6.50)a
NS, not signiﬁcant.
ap < 0.05.
bp < 0.001.
cFor two patients with two sources, the source other than urine was used for
analysis.
TABLE 3. Annual incidence of Kle-
bsiella pneumoniae bacteraemia per
100 000 inhabitants in Sherbrooke,
Canada
1997–1998 1999–2000 2001–2002 2003–2004 2005–2006 2007
Total 10.2 12.2 15.5 15.6 17.8 18.7
Age groups
<18 years
All 0.0 1.6 0.0 1.7 9.9 6.6
18–64 years
All 2.7 4.2 5.2 4.6 9.1 7.0
Non-diabetic 5.6 5.5 8.6 5.3 NA NA
Diabetic 0.0 111.8 64.7 112.6 NA NA
‡65 years
All 67.3 71.7 94.1 93.7 73.1 93.4
Non-diabetic 108.1 113.2 167.9 151.8 NA NA
Diabetic 335.1 358.4 317.2 401.6 NA NA
Site of acquisition
Community 3.5 4.2 4.5 6.1 3.7 5.3
Healthcare-associated 3.2 3.1 5.9 5.1 6.7 6.0
Hospital 3.5 4.9 5.2 4.4 7.4 7.3
NA, not available.
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was, in Canada as elsewhere, an increase in the prevalence
of diabetes mellitus, a condition strongly associated with
K. pneumoniae infection. In Quebec, prevalence of diabetes
among adults increased from 4.3% in 1997–1998 to 6.4% in
2003–2004, a 49% relative increase [16]. In Sherbrooke,
from 1997 to 2004, prevalent cases of diabetes increased by
58% in individuals aged 18–64 years and by 41% among those
aged ‡65 years; in 2004, prevalence of diabetes was 3.6%
among the former and 14.3% in the latter group. During this
period, there was no change in the accessibility to health
care, or in the criteria used by physicians to diagnose diabe-
tes. The incidence of K. pneumoniae bacteraemia remained
fairly stable in each of the age- and diabetes-speciﬁc strata.
Thus, increases in the number of diabetics to a large extent
accounted for the secular changes in the incidence of K. pneu-
moniae bacteraemia. The age gradient may reﬂect exposure
to the pathogen within healthcare settings, a higher fre-
quency of biliary or urinary tracts anomalies, or senescence
of the immune response.
In Taiwan, diabetes was found in 40% of patients with
K. pneumoniae bacteraemia and 70% of those with liver
abscess [2,3]. Elsewhere, one-fourth to one-half of patients
with K. pneumoniae bacteraemia were diabetic [2,17–19].
Among our adult patients, 32% (45% in 2005–2007) were
diabetic. Diabetes has complex impacts on immunity, notably
an impairment of neutrophilic functions (chemotaxis,
adherence, phagocytosis and intracellular killing) [20].
Streptozotocin-induced diabetes led to a higher mortality
among mice experimentally infected with K. pneumoniae
[21]. Phagocytosis of K1/K2 K. pneumoniae isolates by
neutrophils is reduced among diabetic patients with poor
glycaemic control compared with diabetics with adequate
glycaemic control or healthy non-diabetics [22]. Diabetics
are also more likely to develop infections caused by Staphy-
lococcus aureus, Streptococcus pneumoniae, S. agalactiae and
Mycobacterium tuberculosis [23], but this is the ﬁrst time that
a population impact of diabetes on any given infection has
been documented.
Risk factors for mortality were similar to those reported
in previous studies: hospital acquisition, pneumonia as the
source, bacteraemia of unknown source, inappropriate treat-
ment [23–25]. In previous reports, nosocomial bacteraemia
were more likely to be caused by antibiotic resistant strains
[25]. In our population, resistance to third-generation cepha-
losporins and ciproﬂoxacin was remarkably uncommon; the
higher mortality among nosocomial cases may result from
co-morbidities, whereas polymicrobial bacteraemia may
reﬂect a more severe underlying process. Of note, diabetes
was not associated with a higher mortality, in ours as well as
in previous studies.
In conclusion, we have documented the second case of
magA+ rmpA+ hypermucoviscosity phenotype K. pneumoniae
infection in Canada, probably imported from North Africa,
but without epidemiological evidence of local transmission.
We measured for the ﬁrst time the population incidence of
K. pneumoniae bacteraemia, which increased by 82% between
1997 and 2007, to some extent a consequence of the huge
increase in the number of adult diabetics. Sedentary life style,
chronic diseases and infections may interact in the trend.
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